Tan Hongyan, Zhang Bin, Kang Xiawei, Wang Lvyao, Qiu Xiao, Hu Xiangyu
Department of Dermatology, Chongqing Hospital of Traditional Chinese Medicine, Chongqing, 400011, People's Republic of China.
Clin Cosmet Investig Dermatol. 2024 Aug 26;17:1917-1920. doi: 10.2147/CCID.S470170. eCollection 2024.
At present, we have entered the era of using biological agents and small molecule targeted drugs to treat diseases. Although there have been many reports of biological agents treating pityriasis rubra pilaris recently, the clinical application of the JAK inhibitors in the treatment of pityriasis rubra pilaris has been rarely reported, and there is a lack of evidence on the safety and efficacy of these drugs. We explore the use of the JAK inhibitor tofacitinib in the treatment of pityriasis rubra pilaris with significant efficacy and no significant side effects, providing new ideas for the clinical treatment of pityriasis rubra pilaris.
We cover a case of pityriasis rubra pilaris treated with the JAK inhibitor tofacitinib, which showed significant efficacy without any adverse effects.
This case report showed that the JAK inhibitor tofacitinib had significant clinical efficacy in the treatment of pityriasis rubra pilaris. We speculated that the treatment of pityriasis rubra pilaris with the JAK inhibitors may be related to blocking the activation of the JAK/STAT pathway, thereby blocking the high expression of cytokines IL-17, IL-12/IL-23, IL-23, TNF-α.
The JAK inhibitor tofacitinib can become a new option for treating pityriasis rubra pilaris.
目前，我们已进入使用生物制剂和小分子靶向药物治疗疾病的时代。尽管最近有许多关于生物制剂治疗毛发红糠疹的报道，但JAK抑制剂在毛发红糠疹治疗中的临床应用报道较少，且缺乏这些药物安全性和有效性的证据。我们探索使用JAK抑制剂托法替布治疗毛发红糠疹，疗效显著且无明显副作用，为毛发红糠疹的临床治疗提供新思路。
我们报道1例使用JAK抑制剂托法替布治疗的毛发红糠疹病例，疗效显著且无任何不良反应。
该病例报告显示，JAK抑制剂托法替布在毛发红糠疹治疗中具有显著临床疗效。我们推测，JAK抑制剂治疗毛发红糠疹可能与阻断JAK/STAT通路的激活有关，从而阻断细胞因子IL-17、IL-12/IL-23、IL-23、TNF-α的高表达。
JAK抑制剂托法替布可成为治疗毛发红糠疹的新选择。
